Sumatriptan Succinate Injection

Sumatriptan Succinate Injection

Product Summary

Therapeutic Area: This product is distributed by: MCP Pharmaceuticals, LLC.

Full Prescribing Information

MSDS Sheets

Sumatriptan Succinate Injection MSDS

DESCRIPTION Sumatriptan succinate injection is a selective 5-hydroxytryptamine1 receptor subtype agonist. It is a clear, colorless to pale yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 0.5 mL of sumatriptan succinate injection contains 6 mg of sumatriptan (base) as the succinate salt and 3.5 mg of sodium chloride, USP in Water for Injection, USP. The pH range of the solution is approximately 4.2 to 5.3. The osmolality of the injection is 291 mOsmol.

INDICATION AND USAGE Sumatriptan succinate injection is indicated for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster headache episodes.

CONTRAINDICATIONS Sumatriptan succinate injection should not be given intravenously because of its potential to cause coronary vasospasm. Sumatriptan succinate injection should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive sumatriptan succinate injection. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease.

Because sumatriptan succinate injection may increase blood pressure, it should not be given to patients with uncontrolled hypertension.

Sumatriptan succinate injection and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should sumatriptan succinate injection and another 5-HT1 agonist.

Sumatriptan succinate injection should not be administered to patients with hemiplegic or basilar migraine.

Sumatriptan succinate injection is contraindicated in patients with hypersensitivity to sumatriptan or any of its components.

Sumatriptan succinate injection is contraindicated in patients with severe hepatic impairment.

Please see the full prescribing information link above for additional information.

Documents marked with this icon are presented in Portable Document Format (PDF) to retain the original format. To view or print this document, you must use the Adobe® Acrobat® Reader®. Acrobat® Reader® is free and available directly from Adobe’s Web site with full installation instructions. You can either view and print this document or save it to your computer’s hard drive to open later. Your method may vary depending on your operating system and browser type.

“Adobe” and “the Adobe logo” are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.


Return To The Products Listings Page